scholarly journals Other Solid Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Abby Fuoto, DNP, ANP-BC, AOCNP ◽  
Mee-young Lee, MSN, ANP-BC
Keyword(s):  
Monoclonal Antibody ◽  
Annual Meeting ◽  
Nasopharyngeal Cancer ◽  
Cancer Center ◽  
Her2 Amplification ◽  
Advanced Practitioner ◽  
University Of Arizona ◽  
Basket Trial

Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of University of Arizona Cancer Center, considers the implications of a novel monoclonal antibody for nasopharyngeal cancer, and Mee-young Lee, MSN, ANP-BC, of Monter Cancer Center, Northwell, discusses the design of a basket trial for tumors with HER2 amplification or overexpression. Meeting coverage is provided by The ASCO Post.

scholarly journals Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Elizabeth S. Waxman, RN, MSN, AOCN, ANP-BC
Keyword(s):  
Annual Meeting ◽  
Early Stage ◽  
Cancer Center ◽  
Important Research ◽  
Early Stage Lung Cancer ◽  
Advanced Practitioner ◽  
Thoracic Cancer ◽  
Md Anderson ◽  
Doublet Chemotherapy ◽  
Stage Lung Cancer

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doublet chemotherapy to doublet immunotherapy in advanced-stage NSCLC, the first-in-class KRAS G12C inhibitor sotorasib, and the combination of amivantamab and lazertinib. Coverage provided by The ASCO Post.

scholarly journals Disparities and Access to Care: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Amy Pierre, MSN, ANP-BC
Keyword(s):  
Access To Care ◽  
Annual Meeting ◽  
Cancer Center ◽  
Precision Oncology ◽  
Minority Representation ◽  
Advanced Practitioner

Amy Pierre, MSN, ANP-BC, of Flatiron Health and Memorial Sloan Kettering Cancer Center, considers takeaways from a program targeting minority accrual to oncology trials and a study evaluating minority representation in precision oncology trials.

scholarly journals 1P076 Mechanism of multispecific recognition of monoclonal antibody G2(01D. Protein : Function,Poster,The 52nd Annual Meeting of the Biophysical Society of Japan(BSJ2014))

2014 ◽  
Vol 54 (supplement1-2) ◽  
pp. S153
Author(s):  
Yuji O. Kamatari ◽  
Masayuki Oda ◽  
Takahiro Maruno ◽  
Shohey Shimizu ◽  
Yuji Kobayashi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Annual Meeting ◽  
Protein Function ◽  
Biophysical Society

Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center

2017 ◽  
Vol 24 (2) ◽  
pp. 116-120 ◽  
Author(s):  
Mehmet S Copur ◽  
Curtis Gnewuch ◽  
Megan Schriner ◽  
Mark Tharnish ◽  
Mithat Gonen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Dose Reduction ◽  
Annual Cost ◽  
Metastatic Cancer ◽  
Cost Savings ◽  
Cancer Center ◽  
Potential Cost ◽  
Community Based ◽  
Reduction Group

Purpose Increasing new cancer cases and approval of effective but expensive new drugs extending survival have led to unsustainable cancer care costs. Potential cost savings by a hypothetical dose down-rounding project of monoclonal antibodies at a community-based cancer center is presented. Methods From October 2014 through October 2015, metastatic cancer patients receiving monoclonal antibodies at CHI-Health St Francis Cancer Treatment Center in Grand Island, Nebraska, were identified through electronic health records. A total of 11 different types of monoclonal antibodies that were administered during the study period were identified. Trastuzumab, ofatumumab, and obinutuzumab did not require dose-rounding; thus, they were excluded from the analyses. Available vial size(s) and costs per milligram per average wholesale price for each monoclonal antibody were recorded. Costs of actual amounts prescribed were compared to the costs of theoretically reduced ≤5% and ≤10% doses rounded to the nearest vial sizes. Reduced doses resulting in a decreased number of opened vials qualified for meaningful dose down-rounding and were included in the analysis. Average actual dose reduction percentage resulting in cost savings for both groups was also calculated. Results A total of 728 doses of eight monoclonal antibodies suitable for dose down-rounding were identified. Vial sizes of pembrolizumab and ipilimumab did not allow for a meaningful dose down-rounding. At the ≤5% dose down-rounding, 255 of 728 doses (35%) qualified with a potential annual cost savings of $220,793.80. At the ≤10% dose down-rounding, 526 of 728 doses (72%) qualified with a potential annual cost savings of $454,461.00. The average actual dose reduction was 2.4% for the ≤5% dose reduction group and 4.9% for the ≤10% dose reduction group. Overall average cost savings per qualifying dose reduction was around $865.00. More doses qualified for cost savings in the ≤10% dose reduction group. Significant differences between different monoclonal antibodies for dose rounding at either ≤5% (p = 0.002) or ≤10% (p < 0.001) were observed. Conclusion A practical dose down-rounding procedure may allow significant cost reduction in metastatic cancer setting, where the cure is not the goal. Drug waste can be avoided by convenient vial sizes or can even be eliminated by lyophilized forms like in trastuzumab. Our data reflect the monoclonal antibody use and potential cost savings with the proposed dose down-rounding approach in a community-based cancer program.

scholarly journals Melanoma: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Lisa Kottschade, APRN, MSN, CNP
Keyword(s):  
Annual Meeting ◽  
Mayo Clinic ◽  
Immune Therapy ◽  
Advanced Practitioner

With coverage from The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews data on immune therapy after surgery, the combination of the anti–LAG-3 antibody relatlimab and nivolumab, and a 6.5-year update of combination nivolumab and ipilimumab.

scholarly journals Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Lisa Nodzon, PhD, ARNP, AOCNP
Keyword(s):  
Annual Meeting ◽  
Cancer Center ◽  
University Of Texas ◽  
New Therapies ◽  
Emerging Therapies ◽  
Md Anderson ◽  
The University

Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO Annual Meeting.

scholarly journals NIMOTUZUMAB INDUCED HYPERTENSION(NIH): A MAIDEN CASE REPORT

2017 ◽  
Vol 10 (4) ◽  
pp. 8 ◽  
Author(s):  
Balaji Ommurugan ◽  
Amita Priya ◽  
Navin Patil
Keyword(s):  
Monoclonal Antibody ◽  
Epidermal Growth Factor Receptor ◽  
Monoclonal Antibodies ◽  
Case Report ◽  
Nasopharyngeal Cancer ◽  
Growth Factor Receptor ◽  
Humanized Monoclonal Antibody ◽  
Induced Hypertension ◽  
Squamous Cancer ◽  
Epidermal Growth

ABSTRACT                      Nimotuzumab is one among the latest humanized monoclonal antibody targeting against Epidermal Growth Factor Receptor (EGFR). It is approved for Head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and Nasopharyngeal cancer in China. Hypertension is most common with Bevacizumab and Cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of Nimotuzumab induced hypertension in a 70-year-old man treated for vocal cord carcinoma. KEYWORDS: Nimotuzumab, Hypertension, EGFR, Adverse effects.

A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. TPS3650-TPS3650 ◽  
Author(s):  
Masataka Yagisawa ◽  
Yoshiaki Nakamura ◽  
Takayuki Yoshino ◽  
Yoshito Komatsu ◽  
Shigenori Kadowaki ◽  
...  
Keyword(s):  
Solid Tumor ◽  
Circulating Tumor Dna ◽  
Advanced Solid Tumor ◽  
Her2 Amplification ◽  
Antibody Drug Conjugate ◽  
Her2 Positive ◽  
Cancer Types ◽  
Basket Trial ◽  
Tumor Dna ◽  
Antibody Drug

TPS3650 Background: Trastuzumab deruxtecan, a new HER2-targeting antibody-drug conjugate, has been approved for unresectable or metastatic HER2-positive breast cancer by the Food and Drug Administration. In a phase I/II trial, trastuzumab deruxtecan showed a manageable safety profile and antitumor activity in HER2-positive various cancer types. In addition, a tissue-based HER2 test occasionally cannot identify accurate HER2 status due to spatial and temporal intratumoral heterogeneity, leading to potentially missing an opportunity for responders to receive benefit from anti-HER2-targeted therapy. Circulating tumor DNA (ctDNA) analysis can detect comprehensive somatic genome alterations by assessment of spatial and temporal intratumoral heterogeneity with minimal invasiveness. Methods: We designed an investigator-initiated multicenter phase II basket trial to evaluate efficacy and safety of trastuzumab deruxtecan in advanced solid tumor malignancies with HER2 amplification identified by Guardant360, a 74-gene sequencing ctDNA panel, as a part of the Nationwide Cancer Genome Screening Project (GOZILA study, UMIN000029315). The key eligibility criteria are as follows: 1) Histopathologically confirmed advanced solid tumor malignancy; 2) Identified HER2 amplification by Guardant360; 3) Failed prior standard therapy. The participants will receive intravenously 5.4 mg/kg of trastuzumab deruxtecan every 3 weeks. The primary endpoint is objective response rate (ORR). The planned sample size is 55-65. A Bayesian model considering the potential heterogeneity across cancer types will be applied to detect ORR of 5% versus 25% to a certain level while maintaining the false-positive error rate in each cancer type at 10%. Furthermore, tumor tissue, ctDNA and circulating tumor cells are serially collected and analyzed to investigate the predictive biomarkers and resistance mechanisms. The trial was activated in late 2019. At the time of the abstract submission, 2 patients have been enrolled. This trial is granted by AMED under Grant Number JP18lk0201084. Clinical trial information: JapicCTI-194707 .

Sign in / Sign up

Export Citation Format

Share Document